{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:30:52Z","timestamp":1778657452005,"version":"3.51.4"},"reference-count":4,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","pathologyjournal.rcpa.edu.au","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.pathol.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T02:09:22Z","timestamp":1560564562000},"page":"555-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lymphocyte involvement in nivolumab-induced autoimmune myositis"],"prefix":"10.1016","volume":"51","author":[{"given":"Benjamin","family":"Koh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kilian","family":"Tuite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8152-6252","authenticated-orcid":false,"given":"Jason M.","family":"Dyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2019.02.006_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","article-title":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Tocut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.pathol.2019.02.006_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.pathol.2019.02.006_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: a case report and a literature review","volume":"387","author":"Bourgeois-Vionnet","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.pathol.2019.02.006_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130251830583X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130251830583X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T13:53:18Z","timestamp":1563371598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130251830583X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S003130251830583X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2019.02.006","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocyte involvement in nivolumab-induced autoimmune myositis","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. All rights reserved.","name":"copyright","label":"Copyright"}]}}